Case Control Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2022; 28(33): 4812-4822
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4812
Previous hepatitis B viral infection–an underestimated cause of pancreatic cancer
Sergey Batskikh, Sergey Morozov, Alexey Dorofeev, Zanna Borunova, Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Vladimir Chulanov
Sergey Batskikh, Department of Hepatology, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia
Sergey Morozov, Department of Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia
Alexey Dorofeev, Zanna Borunova, Department of Scientific and Clinical Laboratory Research, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia
Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Vladimir Chulanov, Laboratory of Genetic Technologies, Sechenov University, Moscow 119435, Russia
Dmitry Kostyushev, Sergey Brezgin, Vladimir Chulanov, Division of Biotechnology, Scientific Center for Genetics and Life Sciences, Sirius University of Science and Technology, Sochi 354340, Russia
Vladimir Chulanov, Laboratory of Genetic Technologies and Translational Research, National Medical Research Center for Tuberculosis and Infectious Diseases of Ministry of Health of Russia, Moscow 127994, Russia
Author contributions: Batskikh S and Morozov S designed this study; Batskikh S collected and analyzed the data; Borunova Z, Dorofeev A, Kostyushev D, Brezgin S, Kostyusheva A and Chulanov V performed laboratory analyses; Batskikh S, Morozov S and Kostyushev D prepared the figures; Batskikh S performed statistical analysis; Morozov S and Batskikh S drafted the manuscript; All authors critically revised the manuscript and approved its final version.
Supported by Ministry of Science and Higher Education of Russian Federation, No. FGMF-2022-0005; Russian Science Foundation, No. 20-15-00373; and Moscow Healthcare Department, No. AAAA-A18-118021590196-1.
Institutional review board statement: The study was reviewed and approved by the Local Ethics Committee of Moscow Clinical Research Center, No. 9/2016, dated 12DEC2016 and was conducted in accordance with the Declaration of Helsinki (1968) and its consequent revisions.
Informed consent statement: All subjects signed a written informed consent form before the enrollment.
Conflict-of-interest statement: Dr. Batskikh reports grants from Moscow Department of Health during the conduct of the study; personal fees from ABBVIE, personal fees from MSD, personal fees from R-PHARM, outside the submitted work. Dr. Morozov reports grants from Ministry of Science and Higher Education of Russia, during the conduct of the study; personal fees from AstraZeneca, personal fees from Dr. Falk, personal fees from AlfaSigma, grants from Russian Science Foundation, personal fees from Takeda, outside the submitted work. Dr. Chulanov reports grants from Russian Foundation for Basic Research, grants from Russian Foundation for Basic Research, outside the submitted work. Dr. Kostyushev, Dr. Kostyusheva and Dr. Brezgin report grants from Russian Foundation for Basic Research, grants from Russian Foundation for Basic Research, during the conduct of the study. Dr. Dorofeev and Dr. Borunova have nothing to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sergey Morozov, MD, PhD, Doctor, Senior Researcher, Department of Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition, Biotechnology and Food Safety, Kashirskoye Shosse 21, Moscow 115446, Russia. morosoffsv@mail.ru
Received: April 20, 2022
Peer-review started: April 20, 2022
First decision: June 2, 2022
Revised: June 15, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 7, 2022
Core Tip

Core Tip: Hepatitis B viral (HBV) infection is responsible for different types of cancer. Its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study assessed the prevalence of previous HBV infection and to identify viral biomarkers in patients with PDAC to support the role of the virus in the etiology of this cancer. Anti-HBc-positive subjects had an almost 3-fold greater chance of PDAC compared to the controls. Detection of viral replication and hepatitis B virus X protein expression in the tumor tissue show a possible involvement of HBV infection in pancreatic cancer development. Previous HBV infection is currently an underestimated cause of PDAC.